Vanda Pharmaceuticals Inc. Common Stock (VNDA)
Stock · NASDAQ · Health Care
$5.29as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$5.92
Industry
Biotechnology: Pharmaceutical Preparations
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbance…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 533
- Website
- www.vandapharma.com/
Fundamentals
- 1-day range
- $5.22$5.44
- Market cap
- $314.51M
- P/E (trailing)
- —
- P/E (forward)
- 26.45
- EPS (trailing)
- $-4.05
- Dividend yield
- —
- Beta
- 0.66
- Avg. volume
- 931.7K
52-week range
$4.27$9.94
Next earnings: November 4, 2026 · EPS estimate $-0.67confirmed
How Vanda Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Buy 80%
Hold 20%
Sell 0%
1-year price forecast
High
$20
+278.1%
Median
$11.5
+117.4%
Low
$5.75
+8.7%
Vanda Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VNDAVanda Pharmaceuticals Inc. Common Stock$5.29▼ 2.76%Market cap $314.51MP/E —$4.27$9.94
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1.74▼ 0.00%Market cap $301.10MP/E 84.95$1.54$7.08
- IRDOpus Genetics Inc. Common Stock$3.7▼ 3.90%Market cap $300.54MP/E —$1.17$5.81
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$3.8▼ 2.06%Market cap $331.02MP/E —$1.21$6.95
- FULCFulcrum Therapeutics Inc. Common Stock$3.85▲ 0.00%Market cap $283.06MP/E —$2.83$15.74
- UPBUpstream Bio Inc. Common Stock$6.68▼ 1.62%Market cap $349.38MP/E —$5.85$33.68
- DMACDiaMedica Therapeutics Inc. Common Stock$6.39▼ 5.33%Market cap $351.32MP/E —$5.14$10.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $314.51M | — | $5.29 | ▼ 2.76% | $4.27$9.94 |
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $301.10M | 84.95 | $1.74 | ▼ 0.00% | $1.54$7.08 |
| IRD Opus Genetics Inc. Common Stock | $300.54M | — | $3.7 | ▼ 3.90% | $1.17$5.81 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $331.02M | — | $3.8 | ▼ 2.06% | $1.21$6.95 |
| FULC Fulcrum Therapeutics Inc. Common Stock | $283.06M | — | $3.85 | ▲ 0.00% | $2.83$15.74 |
| UPB Upstream Bio Inc. Common Stock | $349.38M | — | $6.68 | ▼ 1.62% | $5.85$33.68 |
| DMAC DiaMedica Therapeutics Inc. Common Stock | $351.32M | — | $6.39 | ▼ 5.33% | $5.14$10.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular Psoriasisbenzinga · 8/24/2026
- B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12Benzinga · 8/10/2026
- HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20Benzinga · 8/10/2026
- Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/6/2026
- Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M EstimateBenzinga · 8/5/2026
- Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M EstBenzinga · 8/5/2026
Insider Activity
Insider Actions →Acquired
386.7K
Disposed
340.2K
- Daniel Patrick McGuire · June 4, 2026 · Grant80.0K
- Phaedra Chrousos · June 4, 2026 · Grant41.6K
- Charles Cliff Duncan · June 4, 2026 · Grant41.6K
- Anne Sempowski Ward · June 4, 2026 · Grant41.6K
- Tage Honore · June 4, 2026 · Grant41.6K
- Stephen Ray Mitchell · June 4, 2026 · Grant41.6K
- Richard W. Dugan · June 4, 2026 · Grant41.6K
- Stephen Ray Mitchell · May 18, 2026 · Gift25.8K
- Charles Cliff Duncan · April 22, 2026 · Grant57.1K
- Kevin Patrick Moran · March 2, 2026 · Sale42.4K @ $8.27
- Joakim Wijkstrom · March 2, 2026 · Sale30.8K @ $8.27
- Timothy Williams · March 2, 2026 · Sale42.4K @ $8.27
- Gunther Birznieks · March 2, 2026 · Sale42.4K @ $8.27
- Mihael Hristos Polymeropoulos · March 2, 2026 · Sale156.2K @ $8.17
Institutional Ownership
March 31, 2026
- Total shares held
- 44.94M
- Total value held
- $286.71M
- Institutional holders
- 164
Top holders this quarter
- Unknown7.28M
- Unknown3.76M
- Unknown3.02M
- Unknown2.75M
- Unknown2.48M
- Unknown1.88M
- Unknown1.80M
- Unknown1.77M
- Unknown1.60M
- Unknown1.44M
See the full, filterable feed with live charts on the MarketWall dashboard.